Skip to content

Skin Conditions

Clinical Trials for Patients With Dermatological Conditions

Psoriasis

Psoriasis is a chronic inflammatory skin condition associated with red thick scaling. It can occur in children and adults. When mild, psoriasis can be treated with topical steroids. When more severe various oral and injectable medications are available. Multiple new treatments are in clinical trials. Psoriasis is often associated with psoriatic arthritis, metabolic syndrome, diabetes and cardiovascular disease. The severity of psoriasis is associated with body mass, tobacco exposure and drinking alcohol. For more information: https://www.dermnetnz.org/topics/psoriasis ; https://www.aad.org/public/diseases/scaly-skin/psoriasis; https://www.psoriasis.org/

IDEOM (International Dermatology Outcome Measures) is a unique group which unifies the efforts of patients, patient advocacy groups, clinicians, researchers, scientists, pharmaceutical and devices company officials, insurers, and regulatory agencies (FDA, etc) to identify what constitutes successful disease treatment/control from a patient perspective. Anyone interested in helping with this process may qualify to attend the IDEOM meetings. www.dermoutcomes.org

Atopic Dermatitis/Eczema

Atopic Dermatitis, often is referred to as eczema. Eczema refers to multiple different inflammatory rashes. Atopic Dermatitis is a chronic relapsing itchy variant of eczema seen in patients who have, or have family members with “atopy”. Atopy often includes other allergy based disorders seen in the patient and/or relatives: asthma, hay fever, and conjunctivitis, sensitivity to foods, wool as well as other skin and systemic findings. For more information: https://www.dermnetnz.org/topics/atopic-dermatitis ; https://www.aad.org/public/diseases/eczema/atopic-dermatitis ; https://nationaleczema.org/

Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS), also known as Acne Inversa, is a disorder is an inflammatory process that affects the apocrine glands and surrounding tissue. Patients develop frequently painful boils, cysts and scarring tracks in the armpits, groin, buttocks and under breasts. There is no clear understand about what causes the disease. Obesity, alcohol, and tobacco aggravate the severity of the disease. Patient may also suffer from diabetes, metabolic syndrome, heart disease, arthritis, and inflammatory bowel disease. Women may have polycystic ovary disease.

HS is treated with antiibiotics, anti-androgens, steroid injections, immunomodulatory compounds, and biologics. Humira, an anti-TNF is an FDA approved treatment. Unfortunately, there is no treatment which universally controls the disease in all patients. Some patients who fail the medications will have the areas involved surgically removed. Weight loss is associated with significant disease improvement; in some, complete control.

IDEOM (International Dermatology Outcome Measures) is a unique group which unifies the efforts of patients, patient advocacy groups, clinicians, researchers, scientists, pharmaceutical and devices company officials, insurers, and regulatory agencies (FDA, etc) to identify what constitutes successful disease treatment/control from a patient perspective. Anyone interested in helping with this process may qualify to attend the IDEOM meetings. www.dermoutcomes.org

Other helpful links:

https://www.hs-foundation.org/
https://www.aad.org/diseases/a-z/hidradenitis-suppurativa-overviewhttps://www.dermnetnz.org/topics/hidradenitis-suppurativa/

Gorlin Syndrome (Basal Cell Carcinoma Nevus Syndrome, BCCNS)

BCCNS is a genetic disorder affecting the skin as well as multiple internal organs. Patients with this syndrome develop many basal cell carcinomas (BCC’s). Some patients may have dozens of BCCs as children and adolescents. They may have bone abnormalities involving the spine, ribs, extremities as well as jaw bone cysts (KCO’s). The primary genetic defect occurs on chromosome 9 at the PTCH locus. This defect activates the Hedgehog pathway leading to tumor growth. Recently, medications have been developed that inhibit the hedgehog pathway and may help to reduce tumor size and/or prevent new tumors. Nonetheless, these medications have many side effects that may limit their use. New drugs are being developed and tested.

For more information:

https://ghr.nlm.nih.gov/condition/gorlin-syndrome
https://www.dermnetnz.org/topics/basal-cell-naevus-syndrome
https://gorlinsyndrome.org/

Common Warts

Warts are a viral infection caused by exposure to the human papilloma virus (HPV). Over 170 subtypes of HPV have been identified. HPV types 1, 2, 4, and 7 are associated with common warts. Wart infections spread from one person to another through skin contact (No frogs nor toads are involved). Common warts often resolve without treatment within months once the body’s immunity recognised and destroys the virus. In many patients this immunity fails to develop and warts and persist for months to years. Treatments include destruction of the skin infected through cryosurgery (liquid nitrogen), podophyllotoxin; lasers; or electrosurgery; imiquimod is a topical agent used to enhance the immune response to the virus. New treatment are under development of those patient who despite these options fail to respond or cannot tolerate these treatments. https://www.dermnetnz.org/topics/sexually-acquired-human-papillomavirus; https://www.aad.org/public/diseases/contagious-skin-diseases/warts

Acne / Acne Scarring

Acne, or acne vulgaris (common) is an inflammatory process with affects tiny hair follicles on the face, chest, back and shoulders affecting over 90 % of teenagers. It is associated with papules (red bumps), pustules, open comedones (black heads) and closed comedones (tiny white firm papules). Acne usually resolves during the mid-twenties. In some individuals acne may persist into senior years. Factors proposed to be associated with the severity of and persistence of acne include: tobacco, sun, diets high in cholesterol, use of skin and hair products that promote acne (comedogenic products) and abrasive skin care. Treatment response varies among acne patients; new treatments are under development for those who fail to respond to current treatment. Many patients with acne can develop scarring. This may be associated with trauma to the lesions; but equally occurs spontaneously from the acne process on its own. Treatments for acne scarring are under development. https://www.dermnetnz.org/topics/acne ; https://www.aad.org/public/diseases/acne-and-rosacea/acne ; https://www.aad.org/public/diseases/acne-and-rosacea/acne-scars#treatment; https://acneandrosacea.org/

IDEOM (International Dermatology Outcome Measures) is a unique group which unifies the efforts of patients, patient advocacy groups, clinicians, researchers, scientists, pharmaceutical and devices company officials, insurers, and regulatory agencies (FDA, etc) to identify what constitutes successful disease treatment/control from a patient perspective. Anyone interested in helping with this process may qualify to attend the IDEOM meetings. www.dermoutcomes.org

Vitiligo

Vitiligo is felt to be an autoimmune disorder wherein pigment cells are destroyed leaving the skin with white patches. The affected skin appears similar to the coloring of the hides of a calf (latin: vitulo). Vitiligo is not contagious, but can resemble some contagious disorders such as tinea versicolor (common) and pinta (rare). Vitiligo appears to result from a combination of genetic, biochemical, immunological and neurological factors. The disease may run in families. Rarely, it is a sign of mole that is changing toward melanoma. Vitiligo may be associated with other autoimmune disorders such as thyroid disease, diabetes, systemic lupus erythematosus (SLE), alopecia areata, Vitamin B12 deficiency, and Addison disease. The pigment destruction may extend to the retina (eye), the inner ear leading to visual and hearing disorders. More frequently, vitiligo is limited to the skin surface and is not associated with internal disease.

Currently, there is no FDA approved treatments. Various individuals have responded to different topical medications, oral /injected immunomodulatory drugs, diet changes, and UV treatments. When the disease is extensive some patient elect to have the remaining pigment destroyed (such as Michael Jackson).

Other helpful links:

https://vitiligosupport.org/
https://www.aad.org/diseases/a-z/vitiligo-overview
https://www.dermnetnz.org/topics/vitiligo/